Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K3 | Q8IVH8 | 10/20 | 0.54 |
| ▸ | AXL | P30530 | 4/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837510 | 0.84 | MAP4K3 (0.56) | MAP4K3AXL | |
| Hydrochloric Acid SCHEMBL17837948 | 0.83 | MAP4K3 (0.55) | MAP4K3AXL | |
| Hydrochloric Acid SCHEMBL17837676 | 0.83 | MAP4K3 (0.55) | MAP4K3AXL | |
| SCHEMBL17844436 | 0.83 | AXL (0.56) | AXLMAP4K4 | |
| SCHEMBL17837584 | 0.80 | MAP4K3 (0.53) | MAP4K3AXLMAP4K4TLR9TLR8 | |
| SCHEMBL17837978 | 0.79 | MAP4K3 (0.53) | MAP4K3AXLMAP4K4TLR9TLR8 | |
| SCHEMBL17837979 | 0.77 | MAP4K3 (0.53) | MAP4K3AXLMAP4K4TLR9TLR8 | |
| SCHEMBL21254478 | 0.75 | MAP4K3 (0.51) | MAP4K3MAP4K4TLR9TLR8TLR7 | |
| SCHEMBL17837526 | 0.74 | AXL (0.64) | AXL | |
| SCHEMBL17861729 | 0.72 | MAP4K3 (0.50) | MAP4K3AXLMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3233829-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | Pfizer Inc (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | MAP4K3 104/4885AXL 1/4885MAP4K4 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.